Stuttgart - Delayed Quote EUR

26CA.SG,0P0001LWJ8,0 (26CA.SG)

5.22

+0.06

+(1.12%)

As of July 23 at 10:00:00 PM GMT+2. Market Open.

ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

CULVER CITY, Calif., January 27, 2025--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the European Medicines Agency (EMA) has accepted for review and begun assessing the marketing authorization application (MAA) for ANKTIVA (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin (BCG) for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tu

Business Wire 1 hour ago

IBRX
ImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United Kingdom

CULVER CITY, Calif., January 15, 2025--ImmunityBio, Inc. (NASDAQ: IBRX) today announced the completion of the submissions of its marketing authorization applications (MAA) for ANKTIVA® (nogapendekin alfa inbakicept) plus Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors, to both the European Union (EU) European Medicines Agency (EMA) and the United King

Business Wire 11 days ago

IBRX
ImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency

CULVER CITY, Calif., January 15, 2025--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced significant progress in its ongoing discussions with the U.S. Food and Drug Administration (FDA) regarding three areas of its clinical development pipeline in non-muscle invasive bladder cancer (NMIBC) and non-small cell lung cancer (NSCLC).

Business Wire 11 days ago

IBRX
ImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® Is Now Effective

CULVER CITY, Calif., January 06, 2025--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code assigned by the Centers for Medicare & Medicaid Services (CMS) for ANKTIVA® (nogapendekin alfa inbakicept-pmln) became effective January 1, 2025. The U.S. Food and Drug Administration (FDA) approved ANKTIVA with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsiv

Business Wire 21 days ago

IBRX
High Growth Tech Stocks to Watch in December 2024

The United States market has been flat over the last week but is up 24% over the past year, with earnings forecast to grow by 15% annually. In this context of robust growth expectations, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability in a rapidly evolving industry landscape.

Simply Wall St. 27 days ago

IBRX

EXEL

MVIS
D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering

CULVER CITY, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the pricing of its previously announced underwritten public offering of an aggregate of 33,333,334 shares of its common stock at a price to the public of $3.00 per share. ImmunityBio has granted the underwriters a 30-day option to purchase up to an additional 5,000,000 shares of its common stock at the public offering price, less underwriting discounts and com

GlobeNewswire last month

IBRX
ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock

CULVER CITY, Calif., December 11, 2024--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the pricing of its previously announced underwritten public offering of an aggregate of 33,333,334 shares of its common stock at a price to the public of $3.00 per share. ImmunityBio has granted the underwriters a 30-day option to purchase up to an additional 5,000,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. All o

Business Wire last month

IBRX
ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock

CULVER CITY, Calif., December 10, 2024--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. In addition, ImmunityBio expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the offering at the public offering price, less underwriting discounts and commissions.

Business Wire last month

IBRX
Immunitybio Inc. (IBRX): Among the Most Promising Cancer Stocks According to Hedge Funds

We recently compiled a list of the 10 Most Promising Cancer Stocks According to Hedge Funds. In this article, we are going to take a look at where Immunitybio Inc. (NASDAQ:IBRX) stands against the other promising cancer stocks. According to the World Health Organization (WHO), cancer remains one of the leading causes of death globally, responsible […]

Insider Monkey 2 months ago

IBRX
ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment

ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated biotechnology company, and nCartes, Inc., a transformational cloud software platform provider, announced a collaboration agreement aimed at automating and streamlining the data fulfillment process for clinical trials. The goal of the collaboration is to make this essential process easier, faster, and less expensive for ImmunityBio's trial investigators.

PR Newswire 2 months ago

IBRX
High Growth Tech Stocks To Watch In November 2024

Over the last 7 days, the United States market has dropped 1.2%, yet it remains up by 30% over the past year, with earnings expected to grow by 15% per annum in the coming years. In this context of robust annual growth and recent volatility, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on future earnings potential.

Simply Wall St. 2 months ago

WDC

COHR

IBRX
ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months

CULVER CITY, Calif., November 19, 2024--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced compelling new data from its ongoing QUILT 3.032 study. As of November 2024, 100 patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer with carcinoma in situ (NMIBC CIS) have been treated with ANKTIVA® (nogapendekin alfa inbakicept-pmln) in combination with BCG, achieving a 71% complete response (CR) rate. In these responders, the range

Business Wire 2 months ago

IBRX
ImmunityBio Reports Third-Quarter 2024 Financial Results

CULVER CITY, Calif., November 12, 2024--ImmunityBio, Inc. (NASDAQ: IBRX) today announced its financial results for the third-quarter ended September 30, 2024.

Business Wire 2 months ago

IBRX
ImmunityBio Soars 56% in a Day: Is This Cancer Breakthrough the Next $30 Stock?

Game-Changing Cancer Therapy Trial Ignites Investor Frenzy--Will ImmunityBio Hit $30 Soon?

GuruFocus.com 3 months ago

IBRX
First Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma

CULVER CITY, Calif., October 24, 2024--Immunotherapy innovator ImmunityBio, Inc. (NASDAQ: IBRX), announced today that the first patients have been dosed in an initial trial studying the potential of the company’s CAR-NK cell therapy targeting CD-19 in the treatment of non-Hodgkin’s lymphoma (NHL). In the QUILT 106 trial, CD19-targeted high-affinity natural killer (t-haNK) cells are being tested initially as a single agent, and after demonstrating safety, then in combination with standard NHL tre

Business Wire 3 months ago

IBRX
ImmunityBio to Participate in the Jefferies London Healthcare Conference

CULVER CITY, Calif., October 21, 2024--Immunotherapy innovator ImmunityBio, Inc. (NASDAQ: IBRX), announced today that company executives will be participating in the Jefferies London Healthcare Conference, which is taking place November 19-21 at the Waldorf Hilton London.

Business Wire 3 months ago

IBRX
ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer

CULVER CITY, Calif., September 09, 2024--Immunotherapy innovator ImmunityBio, Inc. (NASDAQ: IBRX), today announced positive results from its QUILT 3.055 trial demonstrating long-term extended survival of 14 months to as much as five years for patients with advanced non-small cell lung cancer (NSCLC) being treated with checkpoint inhibitors (CPI). An oral presentation of the data was presented by John Wrangle, M.D., MPH, Associate Professor, Medical University of South Carolina, at the World Cong

Business Wire 4 months ago

IBRX
ImmunityBio’s ANKTIVA® Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA Approval

CULVER CITY, Calif., August 12, 2024--ImmunityBio, Inc. (NASDAQ: IBRX), today announced significant progress in market access, making ANKTIVA® (nogapendekin alfa inbakicept-pmln) widely available to patients through both commercial and government insurance programs. The company also announced plans to expand its bladder cancer program globally, notably in the European Union and India.

Business Wire 5 months ago

IBRX
ImmunityBio Announces Study of ANKTIVA® in Combination with the AdHER2DC Cancer Vaccine as a Potential Therapy to Control Endometrial Cancer

CULVER CITY, Calif., August 06, 2024--Immunotherapy company ImmunityBio, Inc. (NASDAQ: IBRX), today announced the opening of a clinical trial to study ANKTIVA® (nogapendekin alfa inbakicept-pmln) together with the investigational AdHER2DC vaccine (autologous dendritic cells transduced with HER2 expressing adenovirus), in individuals with HER2-expressing endometrial cancer. It marks the latest trial involving ANKTIVA, the company’s IL-15 superagonist immune enhancer, to evaluate ANKTIVA as an age

Business Wire 5 months ago

IBRX
Chief Scientific Officer Patrick Soon-Shiong, ImmunityBio, Inc.'s (NASDAQ:IBRX) largest shareholder sees value of holdings go down 6.5% after recent drop

Key Insights Insiders appear to have a vested interest in ImmunityBio's growth, as seen by their sizeable ownership A...

Simply Wall St. 5 months ago

IBRX

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

26CA.SG,0P0001LWJ8,0 (26CA.SG)

ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

ImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United Kingdom

ImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency

ImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® Is Now Effective

High Growth Tech Stocks to Watch in December 2024

D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering

ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock

ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock

Immunitybio Inc. (IBRX): Among the Most Promising Cancer Stocks According to Hedge Funds

ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment

High Growth Tech Stocks To Watch In November 2024

ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months

ImmunityBio Reports Third-Quarter 2024 Financial Results

ImmunityBio Soars 56% in a Day: Is This Cancer Breakthrough the Next $30 Stock?

First Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma

ImmunityBio to Participate in the Jefferies London Healthcare Conference

ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer

ImmunityBio’s ANKTIVA® Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA Approval

ImmunityBio Announces Study of ANKTIVA® in Combination with the AdHER2DC Cancer Vaccine as a Potential Therapy to Control Endometrial Cancer

Chief Scientific Officer Patrick Soon-Shiong, ImmunityBio, Inc.'s (NASDAQ:IBRX) largest shareholder sees value of holdings go down 6.5% after recent drop